MAP4K1 inhibitors

A compound of formula I:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• A1 and A2 are selected from N and CH;
• A3 is selected from CH and N;
• X is selected from C1-3 alkyl, OR6, NHR7 and halogen;
• B is selected from CR11 and N, Y is selected from N and CR12, and the bond between Y and B is a double bond;
• or
• B is C(O), Y is NR14, and the bond between Y and B is a single bond;
• or Y and B taken together form a 5 to 7-membered heterocycle or C5-6 cycloalkyl, and the bond between Y and B is a double bond, wherein said heterocycle or cycloalkyl is optionally substituted with 1-6 R8;
• each R8 is independently selected from C1-3 alkyl and OH, or
• two R8 attached to the same carbon form an oxo, or
• two R8 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C3-5 cycloalkyl, or
• two R8 attached to two adjacent carbon atoms taken together with the two adjacent carbon atoms to which they are attached form a C3-6 cycloalkyl, wherein said alkyl and cycloalkyl are optionally substituted with 1-6 halogen;
• R1 and R2 are each independently selected from hydrogen, C1-4 alkyl, C3-5 cycloalkyl, and 3 to 5-membered heterocycle, wherein said alkyl and cycloalkyl are optionally substituted with OH, C1-6alkoxy or 1-6 halogen;
• or
• R1 and R2, taken together with the atoms to which they are attached, form a 4 to 6-membered heterocycle or C3-6 cycloalkyl;
• R3 and R4 are each independently selected from hydrogen, C1-6 alkyl substituted with OR16, C1-6 alkyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle;
• or
• R3 and R4, taken together with the atoms to which they are attached, form a C3-6 cycloalkyl or 4 to 6-membered heterocycle;
• or
• R1 and R3, taken together with the atoms to which they are attached, form a 3 to 6-membered heterocycle;
• R6 is selected from C1-3 alkyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9;
• R7 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9;
• R9 is selected from C1-3 alkyl, C3-6 cycloalkyl substituted with halogen, halogen, C1-3 alkoxy, and OH;
• R11 is selected from hydrogen, COON, CN, halogen, and C1-3 alkoxy;
• R12 is selected from C1-5 alkyl, C4-6 cycloalkyl, 3 to 6-membered heterocycle, NHR13, NR13R13 and OR13, wherein said alkyl, cycloalkyl or heterocycle is optionally substituted with OH, NH2, 1-4 halogen or R15;
• each R13 is independently selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with halogen;
• R14 is selected from C1-6 alkyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl or heterocycle is optionally substituted with 1-6 halogen;
• R15 is OH, C1-3 alkyl or C3-5 cycloalkyl;
• and
• R16 is H or C1-3 alkyl.